Exclusions include prior rituximab plus LEN combination treatment, history of non-hematologic malignancy, congestive heart failure, or known CNS lymphoma. inMIND (NCT04680052, EudraCT2020-004407-13) is currently enrolling, with planned enrollment of 528 R/R FL and 60-90 R/R MZL patients. Ensaio clínico fase II de braço único de pacientes com linfoma da zona marginal extranodal (EMZL). Prevê-se o recrutamento de 130 doentes. ... Registro de ensaios clínicos..
Apr 19, 2021 · inmind (nct04680052), a global, double-blind, placebo-controlled, randomized phase 3 study, is evaluating whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical....
speedo thong mens swimsuits
ginger for ovarian cyst
May 28, 2021 · exclusion criteria include prior rituximab plus len treatment, history of radiotherapy for other diseases (≥25% of bone marrow), nonhematologic malignancy, congestive heart failure (lvef < 50%), active systemic infection, known cns lymphoma, or severe immunocompromised state. inmind (nct04680052, eudract2020-004407-13) is currently enrolling. NCT ID: NCT04680052: Title: A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma..
Clinical Trial # NCT04680052 has 27 locations including Vancouver, Canada for A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus....
request a test promo code